Lu QL - Search Results

1

A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground.

Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP. Yokota T, et al. Among authors: lu ql. Arch Neurol. 2009 Jan;66(1):32-8. doi: 10.1001/archneurol.2008.540. Arch Neurol. 2009. PMID: 19139297 Free PMC article. Review.

2

Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs.

Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E. Yokota T, et al. Among authors: lu ql. Ann Neurol. 2009 Jun;65(6):667-76. doi: 10.1002/ana.21627. Ann Neurol. 2009. PMID: 19288467 Free PMC article.

3

The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T. Lu QL, et al. Mol Ther. 2011 Jan;19(1):9-15. doi: 10.1038/mt.2010.219. Epub 2010 Oct 26. Mol Ther. 2011. PMID: 20978473 Free PMC article. Review.

4

What Can We Learn From Clinical Trials of Exon Skipping for DMD?

Lu QL, Cirak S, Partridge T. Lu QL, et al. Mol Ther Nucleic Acids. 2014 Mar 11;3(3):e152. doi: 10.1038/mtna.2014.6. Mol Ther Nucleic Acids. 2014. PMID: 24618851 Free PMC article. No abstract available.

5

Elusive sources of variability of dystrophin rescue by exon skipping.

Vila MC, Klimek MB, Novak JS, Rayavarapu S, Uaesoontrachoon K, Boehler JF, Fiorillo AA, Hogarth MW, Zhang A, Shaughnessy C, Gordish-Dressman H, Burki U, Straub V, Lu QL, Partridge TA, Brown KJ, Hathout Y, van den Anker J, Hoffman EP, Nagaraju K. Vila MC, et al. Among authors: lu ql. Skelet Muscle. 2015 Dec 1;5:44. doi: 10.1186/s13395-015-0070-6. eCollection 2015. Skelet Muscle. 2015. PMID: 26634117 Free PMC article.

6

Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.

Benny Klimek ME, Vila MC, Edwards K, Boehler J, Novak J, Zhang A, Van der Meulen J, Tatum K, Quinn J, Fiorillo A, Burki U, Straub V, Lu QL, Hathout Y, van Den Anker J, Partridge TA, Morales M, Hoffman E, Nagaraju K. Benny Klimek ME, et al. Among authors: lu ql. J Neuromuscul Dis. 2021;8(s2):S369-S381. doi: 10.3233/JND-210701. J Neuromuscul Dis. 2021. PMID: 34569970

7

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.

Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD. Lu QL, et al. Nat Med. 2003 Aug;9(8):1009-14. doi: 10.1038/nm897. Epub 2003 Jul 6. Nat Med. 2003. PMID: 12847521

8

Antisense therapy corrects nonsense mutation by exon skipping.

Lu QL, Partridge TA. Lu QL, et al. Discov Med. 2003 Dec;3(19):39-44. Discov Med. 2003. PMID: 20705037 Free article.

9

Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.

Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T. Lu QL, et al. Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203. doi: 10.1073/pnas.0406700102. Epub 2004 Dec 17. Proc Natl Acad Sci U S A. 2005. PMID: 15608067 Free PMC article.

10

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.

Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL. Alter J, et al. Among authors: lu ql. Nat Med. 2006 Feb;12(2):175-7. doi: 10.1038/nm1345. Epub 2006 Jan 29. Nat Med. 2006. PMID: 16444267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

155 results

Search Page